Theranostics, Gallium-68, and Other Radionuclides: A Pathway to Personalized Diagnosis and Treatment

Front Matter....Pages i-xviii
Front Matter....Pages 1-1
 68 Ge/ 68 Ga Generators: Past, Present, and Future....Pages 3-16
Overview and Perspectives on Automation Strategies in 68 Ga Radiopharmaceutical Preparations....Pages 17-31
Post-Processing via Cation Exchange Cartridges: Versatile Options....Pages 33-42
 68 Ga Generator Integrated System: Elution–Purification–Concentration Integration....Pages 43-75
Purification and Labeling Strategies for 68 Ga from 68 Ge/ 68 Ga Generator Eluate....Pages 77-87
 67 Ga and 68 Ga Purification Studies: Preliminary Results....Pages 89-97
Front Matter....Pages 99-99
The Diversity of 68 Ga-Based Imaging Agents....Pages 101-131
Nanoparticles and Phage Display Selected Peptides for Imaging and Therapy of Cancer....Pages 133-147
“Click”-Cyclized 68 Ga-Labeled Peptides for Molecular Imaging and Therapy: Synthesis and Preliminary In Vitro and In Vivo Evaluation in a Melanoma Model System....Pages 149-175
Early Experience with 68 Ga-DOTATATE Preparation....Pages 177-188
 68 Ga-Radiopharmaceuticals for PET Imaging of Infection and Inflammation....Pages 189-219
 68 Ga-Labeled Bombesin Analogs for Receptor-Mediated Imaging....Pages 221-256
A Novel 68 Ga-Labeled Pteroic Acid-Based PET Tracer for Tumor Imaging via the Folate Receptor....Pages 257-267
Measurement of Protein Synthesis: In Vitro Comparison of 68 Ga-DOTA-Puromycin, [ 3 H]Tyrosine, and 2-Fluoro-[ 3 H]tyrosine....Pages 269-283
Hypoxia Imaging Agents Labeled with Positron Emitters....Pages 285-299
 177 Lu/ 90 Y Intermediate-Affinity Monoclonal Antibodies Targeting EGFR and HER2/c-neu: Preparation and Preclinical Evaluation....Pages 301-317
Front Matter....Pages 319-319
Divergent Role of 68 Ga-Labeled Somatostatin Analogs in the Workup of Patients with NETs: AIIMS Experience....Pages 321-351
Differential Uptake of 68 Ga-DOTATOC and 68 Ga-DOTATATE in PET/CT of Gastroenteropancreatic Neuroendocrine Tumors....Pages 353-371
High Uptake of 68 Ga-DOTATOC in Spleen as Compared to Splenosis: Measurement by PET/CT....Pages 373-378
Rare Metastases Detected by 68 Ga-Somatostatin Receptor PET/CT in Patients with Neuroendocrine Tumors....Pages 379-384
Front Matter....Pages 319-319
Comparison of Different Positron Emission Tomography Tracers in Patients with Recurrent Medullary Thyroid Carcinoma: Our Experience and a Review of the Literature....Pages 385-393
PET Lung Ventilation/Perfusion Imaging Using 68 Ga Aerosol (Galligas) and 68 Ga-Labeled Macroaggregated Albumin....Pages 395-423
Combined PET/MR Imaging Using 68 Ga-DOTATOC for Radiotherapy Treatment Planning in Meningioma Patients....Pages 425-439
Front Matter....Pages 441-441
A Rare Case of a Large Spinal Meningioma with Mediastinal Extension and Malignant Behavior Classified Histologically as Benign....Pages 443-455
Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors in Germany: First Results of a Multi-institutional Cancer Registry....Pages 457-465
Polish Experience in Peptide Receptor Radionuclide Therapy....Pages 467-478
PRRT as Neoadjuvant Treatment in NET....Pages 479-485
Intraoperative Somatostatin Receptor Detection After Peptide Receptor Radionuclide Therapy with 177 Lu- and 90 Y-DOTATOC (Tandem PRRNT) in a Patient with a Metastatic Neuroendocrine Tumor....Pages 487-496
Personalized Image-Based Radiation Dosimetry for Routine Clinical Use in Peptide Receptor Radionuclide Therapy: Pretherapy Experience....Pages 497-517
The Bad Berka Dose Protocol: Comparative Results of Dosimetry in Peptide Receptor Radionuclide Therapy Using 177 Lu-DOTATATE, 177 Lu-DOTANOC, and 177 Lu-DOTATOC....Pages 519-536
4D SPECT/CT Acquisition for 3D Dose Calculation and Dose Planning in 177 Lu-Peptide Receptor Radionuclide Therapy: Applications for Clinical Routine....Pages 537-550
Peptide Receptor Radionuclide Therapy with 177 Lu Labeled Somatostatin Analogs DOTATATE and DOTATOC: Contrasting Renal Dosimetry in the Same Patient....Pages 551-559
Is There a Correlation Between Peptide Receptor Radionuclide Therapy-Associated Hematological Toxicity and Spleen Dose?....Pages 561-566
Old and New Peptide Receptor Targets in Cancer: Future Directions....Pages 567-576